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Anti-Xa activity in patients with 
hepatocellular carcinoma 
To the Editor,
Patients with chronic liver disease are characterized by various 
disturbances in the haemostatic balance [1]. Ιn hepatocellular 
carcinoma (HCC), several abnormalities of glycosaminoglycans 
(GAGs) compared to normal liver tissue have been reported [2]. 
In particular, endogenous circulating heparan sulfates detected 
by anti-Xa assay were reported in a patient with HCC [3]. In 
our recent study, assessing anti-Xa activity during acute variceal 
bleeding in cirrhotic patients, we found detectable anti-Xa levels 
in HCC patients [4].This study was designed to evaluate the role 
of endogenous heparinoids in HCC patients. 
Our study comprised three groups of subjects: healthy 
individuals (n=10), HCC patients (n=25) and patients with 
other malignancies: cholangiocarcinoma (n=5) and pancreatic 
cancer (n=8). Patients were observed over a median follow up 
period of 27 (9-33) months. The effect of endogenous GAGs 
was measured using a Xa inhibition clotting assay.
The baseline characteristics of the study population are 
shown in Table I. All patients with HCC had undetectable 
anti-Xa. In the group with the other malignancies, three 
patients had detectable anti-Xa (n=3, 23.1%). In the control 
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group, one patient had detectable anti-Xa (n=1, 10%). 
Correlations regarding the anti-Xa status and age of the 
patients, gender, presence of cancer, type of cancer, presence 
of cirrhosis and malignancy stage were performed. All of 
them were non-significant. Between the anti-Xa status in the 
HCC group and in the group with other malignancies and 
the group with pancreatic cancer there was no difference, but 
we found a significant difference between the HCC and the 
cholangiocarcinoma patients (0 and 2 patients, respectively, 
had detectable anti-Xa) (p=0.025). 
A significant difference in survival was determined 
by Kaplan Meier analysis among the different patient 
groups (p=0.012).The median survival time was 30, 29 
and 25 months for the HCC, the pancreatic cancer and the 
cholangiocarcinoma group, respectively. In the model for 
survival analysis which included the type of malignancy, age 
of the patients, malignancy stage, anti-Xa status, presence of 
cirrhosis and development of thrombotic complications during 
follow-up, the only factor which was identified as a prognostic 
factor for survival was the type of cancer. In particular, there 
was a statistically significant difference between patients with 
HCC and patients with cholangiocarcinoma: HR = 5.26, 95%CI 
1.473-18.806 (p=0.011).
The results of this study show that there are no detectable 
endogenous heparinoids in HCC patients. There is no clear 
Table I. Baseline characteristics of the study groups
Group 1 (n=25) Group 2 (n=13) Group 3 (n=10) p value
Age, years (range) 69 (42-93) 71 (59-84) 40 (24-47) 0.001*
Sex male/female (%) 22/3 (88/ 12) 11/ 2 (84.6/ 15.4) 3/ 7 (30/ 70) 0.001
Cirrhosis, n (%) 19 (76) 0 (0) 0 (0) na
CP score (range) 8 (5-23) na na na
CP stage A/B/C (%) 12/ 11/ 1 (48/ 44/ 4) na na na
MELD (range) 6 (5-14) na na na
BCLC stage A/B/C/D (%) 5/ 9/ 4/ 1 (20/ 36/ 16/ 4) na na na
TNM stage I/II/III/IV (%) na 0/ 1/ 3/ 9 (0/ 7.7/ 23.1/ 69.2) na na
Detectable anti-Xa, n (%) 0 (0) 3 (23.2) 1 (10) 0.006
CP: Child Pugh; na: non available; *p=0.3 between group 1 and 2
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explanation for the different results in this versus our previous 
study. However, there is a significant difference between the 
median values of MELD in the HCC group in this study 
compared to the previous one (median MELD: 6 vs10, 
respectively). In addition, the sample size (HCC patients) in 
the first study was small. Lastly, the anti-Xa detection method 
in the two studies was different.
In conclusion, we have shown that there is no anti-Xa 
activity in patients with HCC. There is a need for a further 
investigation of the use of GAGs as prognostic factors in other 
malignancies, as this issue remains controversial. 
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Celiac disease: past, present and future – 
boundless explorations of a disease of modern 
times
To the Editor, 
We read with great interest the recent paper by van Gils et 
al. [1], describing gender and age differences in celiac disease 
(CD) at the time of its diagnosis in The Netherlands. The 
results of a well-conducted retrospective database study among 
members of the Dutch Celiac Society are presented, showing 
an overall ratio of women to men of 2.4:1 and the absence of 
age specificity of CD diagnosis (0-88 years of age), with more 
than one third of population diagnosed in early childhood. In 
adults, median age differed between males and females, with 52 
and 44 years, respectively [1]. The authors rightly postulate that 
this may be probably accounted for by hormonal differences 
between genders, genetic inheritance, and proper medical care 
from which women benefit more than men [1]. Though we 
agree with most of the authors’ comments, we have, however, 
a query on the methods used for CD diagnosis. In the study 
performed, diagnosis relies purely on the histological analysis 
of biopsy specimens without any mention of serological or even 
genetic testing. Traditionally, small-bowel biopsy has played 
a central role since the late 50s [2], but the confirmation of 
CD is currently based on a combination of findings including 
medical history, serology, physical examination and genetic 
testing. Diagnosing CD based on histology samples alone may 
be risky, allowing an overestimation of disease prevalence. At 
present, a special role is attributed to HLA typing due to its 
negative predictive value of almost 100% [3]. 
The geo-epidemiology of CD varies greatly, but several 
reports have shown that CD is increasing in frequency in 
developing areas [4]. The widespread dissemination of CD is 
not surprising, yet there is still a lack of knowledge regarding 
CD epidemiology in some countries, such as Romania. Is CD 
infrequent in our country, or just underdiagnosed? In order 
to find an answer to these questions, our group conducted 
a retrospective study between 2003 and 2013 at a tertiary 
referral centre in Iasi, Romania [5]. When reviewing the yearly 
distribution of patients, an increase in prevalence of CD was 
noted, predominantly among young adult female patients 
(median age 33 years). Extra-intestinal manifestations were 
documented in 32.8% of the patients, proving the versatile 
nature of this autoimmune enteropathy; hence, the need to 
screen “outside the box” [5]. Unpublished data regarding the 
genetic profile of a prospectively enrolled Romanian CD cohort 
shows a 53% predominance of the HLA-DQ2 heterodimer, 
either in homozygous or heterozygous state, 3% DQ2.5/
DQ8 heterozygous genotype, and 7.5% DQ8 genotype in 
heterozygous state, with a DQA1*05 allele frequency of 75% 
and 77.8% for DQB1*02. According to the Allele Frequency 
Net Database, in The Netherlands the prevalence of DQB1*02 
in the general population is estimated to be 23.7%, and 20% 
for DQA1*05. In the Romanian population, it is estimated that 
the frequency of DQB2*02 reaches 31.2%, with no current 
data regarding DQA1*05 prevalence [6]. Further studies are 
required to accurately determine the genetic profile of these 
communities. 
Future efforts should address the need for a national CD 
patient database in order to access reliable and consistent 
information to respond to the specific needs of the Romanian 
society and provide knowledge as well as even prevention tools. 
New epidemiological studies aimed at assessing worldwide 
distribution of CD, the role of environmental factors and 
relevant parameters such as CD predisposing genotypes will 
play a key role in increasing detection rate for this clinical 
chameleon. 
Roxana Maxim, Anca Trifan, Alina Plesa   
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Reply
We thank Trifan and colleagues for their comments on 
our article “Celiac disease in The Netherlands: demographic 
data of members of the Dutch Celiac Society” that was 
published in JGLD in December 2016 [1]. They queried 
the methods used for celiac disease (CD) diagnosis in our 
study, suggesting that diagnosis was based only on biopsy 
results. We agree that adult CD diagnosis has to be based on a 
combination of serological tests, duodenal histology and, when 
recommended, complemented by HLA typing. Since CD is a 
clinical chameleon, the absence of significant symptoms does 
not exclude the diagnosis of CD.   
As stated in the Methods [1], only the date of biopsy and 
diagnosis were recorded in the database. Obviously, this does 
not exclude the appliance of other diagnostic parameters in the 
diagnostic work up in these patients. In fact, it is reasonable 
to assume that most, if not all, patients in The Netherlands 
are diagnosed according to the current diagnostic criteria 
including both biopsy and serology when diagnosed in 
adulthood. 
It is very unlikely that the few patients who were diagnosed 
based on histology only will affect outcome. Such patients 
could possibly suffer from other non-CD causes of villous 
atrophy [2, 3]. 
There is a need for national CD patient registries in different 
countries for epidemiological purposes, but more importantly, 
for gaining a better understanding of the natural history, 
prognosis and complications of this common disease.
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Fatal acute liver failure during Ritonavir-
boosted Paritaprevir, Ombitasvir and 
Dasabuvir plus Ribavirin therapy
To the Editor,
We read with great interest the case report published in 
your journal by Masetti et al. [1] describing a patient with 
acute liver failure during Ritonavir-boosted Paritaprevir, 
Ombitasvir and Dasabuvir plus Ribavirin therapy in a 84-year-
old Caucasian man with chronic compensated hepatitis C virus 
(HCV) genotype 1b cirrhosis. This patient developed hepatic 
failure after 13 days of treatment, without any identifiable 
precipitating factor. In his past medical history the patient had 
had a partial portal vein thrombosis (PVT) completely resolved 
after Fondaparinux treatment. 
We had a similar case, a 65-year-old Caucasian female, 
with compensated HCV genotype 1b cirrhosis, treated with 
the same drug association, who developed acute severe hepatic 
failure three days after the treatment initiation. Our patient 
had had ischemic transitory liver imagistic lesions, initially 
revealed on computer-tomography (CT). The ischemic lesions 
had resolved spontaneously, without liver perfusion defects on 
a later magnetic resonance imaging (MRI) study. She did not 
take other medication. 
At presentation our patient had high levels of bilirubinemia 
(total bilirubin 18 mg/dl, conjugated bilirubin 12 mg/dl), mild 
encephalopathy, no ascites and acute PVT. The protrombin 
time was slightly prolonged (22 seconds). Mild cholestasis 
and hepatocytolysis were identified. No precipitating factor 
or infections were identified. The viral load was 434 UI/ml. 
The evolution was not favorable, with progressive liver failure 
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(higher levels of bilirubin, ascites in the context of low albumin 
levels, severe encephalopathy) till death (after 19 hospitalization 
days). The liver transplantation was declined, considering 
the PVT. An etiology for PVT, e.g. thrombophilia, was not 
documented in our case.  
A possible causative link between the direct-acting-
antivirals (DAAs), the development of PVT and the onset 
of acute severe liver insufficiency was debated. To date, the 
published literature data does not confirm this hypothesis. The 
effect of DAAs on coagulation in HCV-related liver cirrhosis 
was studied by Tripodi et al. [2] in a group of 28 cirrhotic 
patients.  Their results brought arguments for improvement 
of the individual pro- and anticoagulants under the DAAs 
treatment [2]. The authors hypothesized that the DAAs do not 
substantially modify the balance of pro- and anticoagulants, 
but make it more stable at the end of the treatment [2]. 
Portal vein thrombosis can occur in liver cirrhosis; its 
incidence increases with the increasing severity of liver disease, 
and is less than 1% in well-compensated cirrhosis [3]. Literature 
data provides insufficient arguments for the worsening of liver 
function in the presence of PVT [3, 4]. 
In our case, similar to the case presented by Masetti et al. 
[1], an idiosyncratic pattern of drug-related acute liver failure is 
more likely, considering the early onset of clinical manifestation 
(after three days). 
Based on 26 worldwide published cases of hepatic 
decompensation and liver failure in advanced cirrhotic patients 
treated with Viekira Pak (3D) and Technivie (Ombitasvir-
Paritaprevir-Ritonavir plus RBV) [5], the FDA made a safety 
announcement regarding this category of patients. Patients 
with compensated liver cirrhosis and history of PVT should 
be reported and closely monitored.
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Potential pitfalls of Viekira Pak™ therapy in 
patients with HCV genotype 1b cirrhosis
To the Editor,
The paper by Masetti et al. [1] reported a case of acute liver 
failure during Ritonavir-boosted Paritaprevir, Ombitasvir and 
Dasabuvir therapy in a patient with HCV genotype 1b cirrhosis. 
The FDA recommends the Viekira PakTM regimen in patients 
with compensated liver cirrhosis [2]. However, the elevations 
of serum bilirubin, as well as alanine aminotransferase levels 
reported in clinical trials [3] warrant close monitoring during 
therapy.
A 60-year-old HCV genotype 1b infected female patient, 
diagnosed with compensated cirrhosis (Child Pugh A 6 
and MELD 13), treatment-naïve, was admitted to our Unit 
on 19/11/2015 for initiating direct antiviral agents (DAAs) 
regimen. Esophageal varices grade II/III were detected 
without signs of bleeding, and the abdominal ultrasound 
showed no ascites. Baseline serum bilirubin was 2.1 mg/dL 
and international normalized ratio 1.4. The patient denied any 
history of alcohol abuse. 
Fibromax indicated a F4 fibrosis. The alpha-fetoprotein 
was in normal ranges (5.5 IU/mL). The HCV-RNA level was 
1,130,609 IU/mL. On 10/02/2016 the 3D plus RBV treatment 
was initiated. The first assessment after the initiation of therapy 
was performed at week 4, when patient‘s complaints were 
asthenia and fatigue; physical examination revealed jaundice, 
without other signs of hepatic decompensation. 
Within 6 weeks of DAA therapy, the patient was admitted 
with dizziness, drowsiness, confused speech, disorientation, 
bleeding gums, jaundice and flapping tremor. Elevated levels of 
total bilirubin (up to 6.79 mg/dL), international normalized ratio 
levels (INR max 1.81) and low albumin levels (3.04 g/dL) were 
detected (Fig. 1); testing for viral acute hepatitis was negative and 
abdominal ultrasound revealed ascites in the Douglas pouch.
Fig. 1. Changes in laboratories in relation to antiviral therapy. 
Shortly after the initiation of hepatitis C treatment, the laboratory 
levels deteriorated indicating a decline in hepatic sinthetic function. 
After treatment discontinuation, values slowly returned to baseline. 
PODr+R: Paritaprevir, Ombitasvir, Dasabuvir, Ritonavir and 
Ribavirin. BI: total bilirubin. INR: International normalized ratio.
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Given the malaise of the patient, due to the Interferon-
free treatment (the patient denied use of any other drugs in 
the last 6 months), discontinuation was decided. The patient 
was discharged after two weeks on therapy with diuretics and 
hepatoprotective drugs, with progressive remission of ascites 
and without clinical signs of encephalopathy. At three and six 
months after discontinuation of the antiviral therapy HCV 
RNA was assessed and viremia was undetectable.
The case reported by Masetti et al. demonstrates the 
possibility of severe liver failure due to the 3D therapy, 
characterized by grade 4 hyperbilirubinemia and coagulation 
disorders, with only mild elevation of liver enzymes, which is 
consistent with an idiosyncratic pattern of drug related acute 
liver failure [1]. Our case is characterized by two unexpected 
features: the occurrence of liver decompensation under 
an Interferon-free regimen in a patient with Child Pugh A 
cirrhosis and the sustained viral response (SVR) achieved 
already after 6 weeks of treatment. 
Our report highlights the importance of close monitoring 
for liver decompensation. Hyperbilirubinemia represents a 
frequent finding during therapy. Aminotransferase levels do 
not tend to increase in parallel with bilirubin in DAA-related 
liver injury [4]. This pattern could delay the early recognition 
of severe liver injury, which requires therapy discontinuation.
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Assessing mucosal healing in IBD in daily 
practice
To the Editor,
We read with interest the article by Römkens et al. 
regarding the  treatment targets in IBD, as used in clinical 
practice in Nijmegen, The Netherlands [1]. According to the 
authors, the main goal in treating IBD for most of the Dutch 
gastroenterologists is reaching deep remission, most of them 
choosing to intensify treatment in order to obtain it. Mucosal 
healing (MH) is correlated with better outcome (longer 
remission, reduction of hospitalizations, complications and 
surgical resections) [2], being considered as a treatment target 
for 66% of the participants  in the study [1]. For defining MH 
in UC, Mayo score 0-1 was used by 52% of the participants, 
whereas 66% considered MH in CD when “macroscopic 
normal mucosa” was described [1].
We consider that a “macroscopic normal mucosa” is 
rarely obtained, especially in a formerly severe CD. In these 
cases, pseudopolyps or mucosal scars, as residuals of former 
inflammation, appearing on a non-ulcerated mucosa, can be 
interpreted as MH. 
In most of the CD trials (ACCENT 1, MUSIC, SONIC, 
EXTEND), MH is clearly defined as the complete absence of 
ulcers and inflammatory lesions (SES-CD 0, CDEIS 0) [3-7]. 
Unfortunately, in clinical practice, an unequivocal definition of 
MH is lacking; all of the scoring systems published have certain 
limitations. Among the available ones, which are known to 
have a high interobserver variability, SES-CD is the one with 
an excellent inter-observer reliability [8] .
Reading the study by Romkens et al. raised the question 
whether pseudopolyps or mucosal scars in an otherwise 
normal colonic mucosa may also be termed MH, enlarging the 
spectrum of “macroscopic normal mucosa” in CD.
In our case-series, we retrospectively analyzed  a group of 
66 patients with CD, based on the following selection criteria: 
ileocolonic (L3) or colonic extension (L2), inflammatory 
pattern, biological and endoscopic remission on two 
consecutive evaluations, separated by at least 1 year  (biological 
remission considered if CRP<10 mg/l, and/or fecal calprotectin 
<100). Patients with isolated disease or with a history of surgery 
for IBD were excluded. We found no significant differences 
regarding the gender or the extension of the disease in the 
selected group:  48.48% vs 51.51% (F:M, L2:L3). Most of the 
patients maintained the remission with anti-TNF drugs as 
a monotherapy (63.63%) or as a combination therapy with 
AZA (24.24%). 
When MH was first considered, a „normal aspect of the 
macroscopic mucosa” was described in 37.87% of patients. 
The majority of patients (68.18%) lacked the complete 
normalization of the mucosa, but they were still labeled 
as endoscopic remission, if the remaining lesions were 
pseudopolyps (50%) or mucosal scars (18.18%), and no 
ulcerations were visible.
Given the fact that all these patients maintained the 
endoscopic remission after a median time of 2.72 years (range 
1- 8), we believe that an “abnormal” mucosa due to the presence 
of pseudopolyps or mucosal scars should not preclude a 
diagnosis of MH, and no therapeutic effort should be made 
in order to make these lesions withdraw.
In conclusion, a correct distinction between “active” and 
“inactive” IBD is of great importance in clinical practice. In 
CD, a “macroscopic normal mucosa” is a restrictive way to 
define MH, excluding a significant number of cases and leading 
to unnecessary therapeutic changes. Of note, in CD, activity 
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assessment would also require imaging modalities (MaRIA, 
Lemann scores), and “bowel wall healing” rather than MH 
should be desirable.
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Reply,
We thank Gheorghe and colleagues for their interest in 
our work and for their thoughtful comments. We appreciate 
their willingness to share the original data from their cohort 
of 66 Crohn’s disease (CD) patients. The authors highlight 
the complexity of endoscopic scoring of apparently normal 
looking mucosa and show that the proportion of patients with 
‘endoscopic remission’ depends on the used definition. The issue 
at stake is not only to formulate a lucid definition of mucosal 
healing (MH) in inflammatory bowel disease (IBD), but also to 
coin a clear definition of ‘macroscopic normal mucosa’. The aim 
of our nationwide survey was to map treatment targets in daily 
clinical IBD practice, not to propose new scoring systems for IBD.
We found that more than half of the participants use the 
Mayo score (0 or ≤ 1) to define MH in ulcerative colitis (UC), 
with 40% of the participants indicating ‘macroscopic normal 
mucosa’ as MH in UC, and 66% in CD. In CD only one-fifth 
used validated scoring systems as CDEIS and SES-CD, probably 
because of their time-consuming and complex character [1]. 
We agree with the comments of Dr. Gheorghe and colleagues, 
as mentioned in our discussion, that ‘macroscopic normal 
mucosa’ in CD must be interpreted in accordance with the 
IOIBD consensus [2] as ‘absence of ulceration’. 
Clear definitions are indispensable to categorise IBD 
treatment targets.
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